Valuation: Curatis Holding AG

Market Cap 95.42M 118M 102M 86.78M 163M 11.24B 166M 1.12B 437M 5.63B 441M 432M 18.71B P/E 2024
-8.71x
P/E 2025 -42.3x
Enterprise Value 93.55M 115M 99.56M 85.08M 160M 11.02B 163M 1.1B 429M 5.52B 433M 423M 18.34B EV / Sales 2024
8,696,370x
EV / Sales 2025 5,424,304x
Free-Float
21.91%
Yield 2024 *
-
Yield 2025 -
1 day-2.96%
1 week-10.00%
Current month-11.76%
1 month-22.75%
3 months-20.35%
6 months+0.84%
Current year+50.00%
1 week 18
Extreme 18
20.5
1 month 18
Extreme 18
23.9
Current year 11.75
Extreme 11.75
27.9
1 year 10.9
Extreme 10.9
27.9
3 years 5
Extreme 5
27.9
5 years 5
Extreme 5
27.9
10 years 5
Extreme 5
27.9
Date Insider Type Main position Quantity % Market Cap.
1/13/26 Sell 209 0.0041%
1/9/26 Buy 9,000 0.1787%
1/9/26 Sell 5,000 0.0993%
Change 5-day change 1-year change 3-year change Capi.($)
-2.96%-10.00%+51.90% - 118M
-0.31%+2.44%+38.43%+0.77% 80.23B
-1.02%-0.51%-2.54%+28.91% 50.64B
+1.74%-4.04%+10.51%+165.29% 46.87B
-1.39%+0.10%-50.39%-50.07% 46.34B
-0.39%+0.91%+51.39%-20.90% 31B
-0.52%+7.01%+125.98%-35.99% 25.28B
-0.30%-0.33%+38.24%+85.63% 24.36B
+1.65%-2.00%-6.43%+191.59% 20.81B
+3.13%+0.67%+61.35%+118.40% 16.08B
Average +0.08%-0.82%+31.85%+53.74% 34.17B
Weighted average by Cap. +0.07%+0.53%+22.48%+39.14%

Financials

2024 2025
Net sales 6.9 8.5 7.34 6.27 11.79 812.47 11.99 80.8 31.59 406.86 31.9 31.21 1.35K 10.8 13.31 11.49 9.82 18.47 1.27K 18.77 126.54 49.48 637.19 49.96 48.88 2.12K
Net income -4.34M -5.35M -4.62M -3.95M -7.43M -512M -7.55M -50.91M -19.91M -256M -20.1M -19.66M -852M -1.42M -1.74M -1.51M -1.29M -2.42M -167M -2.46M -16.59M -6.49M -83.54M -6.55M -6.41M -278M
Net Debt -3.01M -3.71M -3.21M -2.74M -5.15M -355M -5.24M -35.32M -13.81M -178M -13.94M -13.64M -591M -1.87M -2.3M -1.99M -1.7M -3.19M -220M -3.24M -21.88M -8.55M -110M -8.64M -8.45M -366M
Logo Curatis Holding AG
Curatis Holding AG formerly Kinarus Therapeutics Holding AG is a Switzerland-based company that operates in specialty pharmaceutical and therapeutic drug industry. The Company conducts its work within clinical-stage area and focuses on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of diseases. This is done by distributing specialty pharmaceuticals throughout Switzerland, with aims to expanded to larger European markets such as Germany, France, United Kingdom as well as Italy. The drugs and treatments produced are primarily developed in order to treat rare diseases, often referred to as orphan diseases, which receive little funding, relative to more common disorders.
Employees
9
Date Price Change Volume
26-08-14 CHF 18.00 -2.96% 3,972
26-08-13 CHF 18.55 -4.38% 2,665
26-08-12 CHF 19.40 -1.77% 1,490
26-08-11 CHF 19.75 -2.71% 760
26-08-10 CHF 20.30 +1.50% 717
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CURN Stock